Stay updated on PET-Directed Therapy With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the PET-Directed Therapy With Pembrolizumab Clinical Trial page.

Latest updates to the PET-Directed Therapy With Pembrolizumab Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov record for a phase 2 study of pembrolizumab and chemotherapy in classical Hodgkin lymphoma is displayed instead of a 403 error page.SummaryDifference83%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site's revision identifier changes from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content. It appears above the unavailable study record.SummaryDifference1%

- Check33 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe ClinicalTrials.gov study page continues to display a 403 Forbidden error. Its footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check47 days agoChange DetectedThe study page now shows a 403 Forbidden error page, replacing the trial details with a standard site error screen.SummaryDifference0.5%

Stay in the know with updates to PET-Directed Therapy With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PET-Directed Therapy With Pembrolizumab Clinical Trial page.